IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreAs WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read moreTo better understand this resulting dichotomy, this white paper answers five key questions, with a focus on applications related to innovation in the life sciences sector and the COVID-19 pandemic.
Read more